BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
Ligands for the bromodomain and extra-terminal domain (BET) family of bromodomains have shown promise as useful therapeutic agents for treating a range of cancers and inflammation. Here we report that our previously developed 3,5-dimethylisoxazole-based BET bromodomain ligand (OXFBD02) inhibits inte...
Main Authors: | Jennings, L, Schiedel, M, Hewings, D, Picaud, S, Laurin, C, Bruno, P, Bluck, J, Scorah, A, See, L, Reynolds, J, Moroglu, M, Mistry, I, Hicks, A, Guzanov, P, Clayton, J, Evans, C, Stazi, G, Biggin, P, Mapp, A, Hammond, E, Humphreys, P, Filippakopoulos, P, Conway, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2018
|
Similar Items
-
Developing chemical probes for the BET bromodomains
by: Hewings, D, et al.
Published: (2012) -
The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
by: Hay, D, et al.
Published: (2013) -
BRD3 and BRD4 BET bromodomain proteins differentially regulate skeletal myogenesis
by: Roberts, T, et al.
Published: (2017) -
Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010) -
Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010)